Published in QJM on November 13, 2009
Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A (2011) 2.39
Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2010) 2.28
Protective effects of dietary avocado oil on impaired electron transport chain function and exacerbated oxidative stress in liver mitochondria from diabetic rats. J Bioenerg Biomembr (2015) 2.01
IL-17 signaling accelerates the progression of nonalcoholic fatty liver disease in mice. Hepatology (2014) 1.69
The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis. J Gastroenterol (2012) 1.30
Role of ceramides in nonalcoholic fatty liver disease. Trends Endocrinol Metab (2012) 1.20
Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease. World J Gastroenterol (2012) 1.13
Upregulation of hemoglobin expression by oxidative stress in hepatocytes and its implication in nonalcoholic steatohepatitis. PLoS One (2011) 1.08
Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease. Toxicol Appl Pharmacol (2013) 1.08
Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease. Lipids Health Dis (2011) 1.06
Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol (2014) 1.05
The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD). Lipids Health Dis (2010) 1.03
Fatty liver index predicts further metabolic deteriorations in women with previous gestational diabetes. PLoS One (2012) 1.00
Phenotypic comparison of common mouse strains developing high-fat diet-induced hepatosteatosis. Mol Metab (2013) 1.00
Shear wave dispersion measures liver steatosis. Ultrasound Med Biol (2011) 1.00
Limited therapeutic effect of N-acetylcysteine on hepatic insulin resistance in an experimental model of alcohol-induced steatohepatitis. Alcohol Clin Exp Res (2011) 0.98
Modulation of hepatic steatosis by dietary fatty acids. World J Gastroenterol (2014) 0.95
Distinct effects of calorie restriction and resveratrol on diet-induced obesity and Fatty liver formation. J Nutr Metab (2011) 0.95
Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment. Int J Mol Sci (2013) 0.94
Simvastatin ameliorates liver fibrosis via mediating nitric oxide synthase in rats with non-alcoholic steatohepatitis-related liver fibrosis. PLoS One (2013) 0.92
Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Mayo Clin Proc (2015) 0.90
Probiotics and Nonalcoholic Fatty liver Disease. Middle East J Dig Dis (2013) 0.88
Interactions between hepatic iron and lipid metabolism with possible relevance to steatohepatitis. World J Gastroenterol (2012) 0.87
Advances in the treatment of nonalcoholic fatty liver disease. Ther Adv Endocrinol Metab (2010) 0.86
Association between metabolic syndrome and the development of non-alcoholic fatty liver disease. Exp Ther Med (2013) 0.84
Potential epigenetic mechanism in non-alcoholic Fatty liver disease. Int J Mol Sci (2015) 0.84
Peroxisome proliferator-activated receptor α activation induces hepatic steatosis, suggesting an adverse effect. PLoS One (2014) 0.84
Epigenetic mechanisms underlying the link between non-alcoholic fatty liver diseases and nutrition. Nutrients (2014) 0.84
BL153 partially prevents high-fat diet induced liver damage probably via inhibition of lipid accumulation, inflammation, and oxidative stress. Oxid Med Cell Longev (2014) 0.83
Inhibition of Glutaminyl Cyclases alleviates CCL2-mediated inflammation of non-alcoholic fatty liver disease in mice. Int J Exp Pathol (2013) 0.83
A cell-type-specific role for murine Commd1 in liver inflammation. Biochim Biophys Acta (2014) 0.83
Non-alcoholic fatty liver disease and diabetes. Metabolism (2016) 0.82
Evaluation of Aroclor 1260 exposure in a mouse model of diet-induced obesity and non-alcoholic fatty liver disease. Toxicol Appl Pharmacol (2014) 0.82
Dietary protein affects gene expression and prevents lipid accumulation in the liver in mice. PLoS One (2012) 0.82
Current and Future Burden of Chronic Nonmalignant Liver Disease. Clin Gastroenterol Hepatol (2015) 0.81
A network biology workflow to study transcriptomics data of the diabetic liver. BMC Genomics (2014) 0.81
MicroRNA-27a decreases the level and efficiency of the LDL receptor and contributes to the dysregulation of cholesterol homeostasis. Atherosclerosis (2015) 0.81
Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease. World J Gastroenterol (2014) 0.81
Elevated alanine aminotransferase activity is not associated with dyslipidemias, but related to insulin resistance and higher disease grades in non-diabetic non-alcoholic fatty liver disease. Asian Pac J Trop Biomed (2012) 0.81
MicroRNAs in liver fibrosis: Focusing on the interaction with hedgehog signaling. World J Gastroenterol (2016) 0.80
Lessons from hepatocyte-specific Cyp51 knockout mice: impaired cholesterol synthesis leads to oval cell-driven liver injury. Sci Rep (2015) 0.80
Association between Insulin Resistance, Metabolic Syndrome and Nonalcoholic Fatty Liver Disease in Chinese Adults. Iran J Public Health (2012) 0.80
The effect of taurine on hepatic steatosis induced by thioacetamide in zebrafish (Danio rerio). Dig Dis Sci (2011) 0.79
Metabolomic signatures in lipid-loaded HepaRGs reveal pathways involved in steatotic progression. Obesity (Silver Spring) (2013) 0.79
Characterization of hepatic lipid profiles in a mouse model with nonalcoholic steatohepatitis and subsequent fibrosis. Sci Rep (2015) 0.79
Prevalence of non-alcoholic fatty liver disease in four different weight related patient groups: association with small bowel length and risk factors. BMC Res Notes (2015) 0.79
Non-alcoholic fatty liver disease and psoriasis: So far, so near. World J Hepatol (2015) 0.79
Hyperinsulinemia shifted energy supply from glucose to ketone bodies in early nonalcoholic steatohepatitis from high-fat high-sucrose diet induced Bama minipigs. Sci Rep (2015) 0.79
Manifestations of fasting-induced fatty liver and rapid recovery from steatosis in voles fed lard or flaxseed oil lipids. Nutrients (2013) 0.79
Metabolic syndrome: A review of the role of vitamin D in mediating susceptibility and outcome. World J Diabetes (2015) 0.78
Alloxan-induced diabetes causes morphological and ultrastructural changes in rat liver that resemble the natural history of chronic fatty liver disease in humans. J Diabetes Res (2015) 0.78
Use of fibrates in the metabolic syndrome: A review. World J Diabetes (2016) 0.78
Comparison between the efficacies of curcumin and puerarin in C57BL/6 mice with steatohepatitis induced by a methionine- and choline-deficient diet. Exp Ther Med (2013) 0.78
Pathogenesis of Nonalcoholic Steatohepatitis: Interactions between Liver Parenchymal and Nonparenchymal Cells. Biomed Res Int (2016) 0.78
Fibroscan Compared to FIB-4, APRI, and AST/ALT Ratio for Assessment of Liver Fibrosis in Saudi Patients With Nonalcoholic Fatty Liver Disease. Hepat Mon (2016) 0.77
The Potential of Non-Provitamin A Carotenoids for the Prevention and Treatment of Non-Alcoholic Fatty Liver Disease. Biology (Basel) (2016) 0.77
Lack of hepcidin expression attenuates steatosis and causes fibrosis in the liver. World J Hepatol (2016) 0.77
Relevance of low testosterone to non-alcoholic fatty liver disease. Cardiovasc Endocrinol (2015) 0.77
Characteristics of nonalcoholic fatty liver disease induced in wistar rats following four different diets. Nutr Res Pract (2015) 0.77
Gut Microbiota: Association with NAFLD and Metabolic Disturbances. Biomed Res Int (2015) 0.77
The differential effects of low birth weight and Western diet consumption upon early life hepatic fibrosis development in guinea pig. J Physiol (2016) 0.77
Dietary walnut reduces hepatic triglyceride content in high-fat-fed mice via modulation of hepatic fatty acid metabolism and adipose tissue inflammation. J Nutr Biochem (2016) 0.76
From NAFLD to Cardiovascular Disease. Is it (Still) the Metabolic Syndrome? Clujul Med (2014) 0.76
Effect of fibrate treatment on liver function tests in patients with the metabolic syndrome. Springerplus (2014) 0.76
Research advances in the relationship between nonalcoholic fatty liver disease and atherosclerosis. Lipids Health Dis (2015) 0.76
Thymoquinone alleviates nonalcoholic fatty liver disease in rats via suppression of oxidative stress, inflammation, apoptosis. Naunyn Schmiedebergs Arch Pharmacol (2016) 0.76
Ces3/TGH Deficiency Attenuates Steatohepatitis. Sci Rep (2016) 0.76
Helicobacter pylori infection is not associated with nonalcoholic fatty liver disease. World J Gastroenterol (2016) 0.76
Intervening TNF-α via PPARγ with Gegenqinlian Decoction in Experimental Nonalcoholic Fatty Liver Disease. Evid Based Complement Alternat Med (2015) 0.76
Childhood energy intake is associated with nonalcoholic fatty liver disease in adolescents. J Nutr (2015) 0.76
Associations between Methylenetetrahydrofolate Reductase (MTHFR) Polymorphisms and Non-Alcoholic Fatty Liver Disease (NAFLD) Risk: A Meta-Analysis. PLoS One (2016) 0.76
Hepatocellular carcinoma in nonalcoholic fatty liver disease mimicking benign hemangioma: two case reports and literature review. Int J Clin Exp Pathol (2015) 0.76
Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances. J Pathol (2016) 0.75
Elements: in this month's issue. QJM (2010) 0.75
Acquisition of lipid metabolic capability in hepatocyte-like cells directly induced from mouse fibroblasts. Front Cell Dev Biol (2014) 0.75
Effects of cumin on nonalcoholic steatohepatitis: A double blind, randomised, controlled trial. Adv Biomed Res (2015) 0.75
Hyper- and hypo- nutrition studies of the hepatic transcriptome and epigenome suggest that PPARα regulates anaerobic glycolysis. Sci Rep (2017) 0.75
Celastrol ameliorates liver metabolic damage caused by a high-fat diet through Sirt1. Mol Metab (2016) 0.75
Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia. Sci Rep (2017) 0.75
The Flexibility of Ectopic Lipids. Int J Mol Sci (2016) 0.75
Circulating miRNA in patients with non-alcoholic fatty liver disease and coronary artery disease. BMJ Open Gastroenterol (2016) 0.75
Treating morbid obesity in cirrhosis: A quest of holy grail. World J Hepatol (2015) 0.75
Ceramide Induces Human Hepcidin Gene Transcription through JAK/STAT3 Pathway. PLoS One (2016) 0.75
Hepatic steatosis and fibrosis: Non-invasive assessment. World J Gastroenterol (2016) 0.75
Oligonol suppresses lipid accumulation and improves insulin resistance in a palmitate-induced in HepG2 hepatocytes as a cellular steatosis model. BMC Complement Altern Med (2015) 0.75
Detection of pathways affected by positive selection in primate lineages ancestral to humans. Mol Biol Evol (2017) 0.75
Physical Activity Is Prospectively Associated With Adolescent Nonalcoholic Fatty Liver Disease. J Pediatr Gastroenterol Nutr (2016) 0.75
The Angiogenesis Inhibitor ALS-L1023 from Lemon-Balm Leaves Attenuates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease through Regulating the Visceral Adipose-Tissue Function. Int J Mol Sci (2017) 0.75
Steatosis Grade is the Most Important Risk Factor for Development of Endothelial Dysfunction in NAFLD. Medicine (Baltimore) (2016) 0.75
The Circulating CTRP13 in Type 2 Diabetes and Non-Alcoholic Fatty Liver Patients. PLoS One (2016) 0.75
The clinical significance of serum ferritin in pediatric non-alcoholic Fatty liver disease. Pediatr Gastroenterol Hepatol Nutr (2014) 0.75
The Effects of Melatonin in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial. Adv Biomed Res (2017) 0.75
Conjugated linoleic acid improves glycemic response, lipid profile, and oxidative stress in obese patients with non-alcoholic fatty liver disease: a randomized controlled clinical trial. Croat Med J (2016) 0.75
Sodium 4-phenylbutyrate prevents murine dietary steatohepatitis caused by trans-fatty acid plus fructose. J Clin Biochem Nutr (2015) 0.75
Silencing of FABP1 ameliorates hepatic steatosis, inflammation, and oxidative stress in mice with nonalcoholic fatty liver disease. FEBS Open Bio (2017) 0.75
Persistent Endocrine-Disrupting Chemicals and Fatty Liver Disease. Curr Environ Health Rep (2017) 0.75
Effects of Azilsartan, Aliskiren or their Combination on High Fat Diet-induced Non-alcoholic Liver Disease Model in Rats. Med Arch (2017) 0.75
Yinchen Linggui Zhugan Decoction Ameliorates Nonalcoholic Fatty Liver Disease in Rats by Regulating the Nrf2/ARE Signaling Pathway. Evid Based Complement Alternat Med (2017) 0.75
Regional differences in genetic susceptibility to non-alcoholic liver disease in two distinct Indian ethnicities. World J Hepatol (2017) 0.75
eIF2α phosphorylation is required to prevent hepatocyte death and liver fibrosis in mice challenged with a high fructose diet. Nutr Metab (Lond) (2017) 0.75
Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology (2004) 18.86
NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature (2004) 15.14
Steatohepatitis: a tale of two "hits"? Gastroenterology (1998) 13.21
Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science (2001) 11.56
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med (2006) 10.97
Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med (2005) 10.88
Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol (2006) 10.67
Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology (2006) 10.05
Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest (2005) 9.09
Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology (2003) 8.75
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology (2001) 8.09
Secretion of microbicidal alpha-defensins by intestinal Paneth cells in response to bacteria. Nat Immunol (2000) 6.62
Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet (2007) 5.74
Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR) Diabet Med (1999) 5.59
The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest (2003) 5.32
Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest (2008) 5.27
Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology (2005) 5.11
Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology (2003) 4.95
Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology (2007) 4.83
ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab (2002) 4.64
Translational control in the endoplasmic reticulum stress response. J Clin Invest (2002) 4.56
Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care (2007) 4.42
Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest (2007) 4.41
Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev (2002) 4.41
Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology (2009) 4.16
Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology (2003) 4.03
The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab (2007) 4.01
Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology (2004) 3.93
GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice. J Clin Invest (2009) 3.70
Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol (2006) 3.59
Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology (2003) 3.51
Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA (2003) 3.51
Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology (2004) 3.23
Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology (2007) 3.18
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol (2005) 3.17
Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. Liver Int (2009) 3.12
Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol (2008) 3.03
Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology (2004) 3.00
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology (2004) 2.98
NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology (2002) 2.96
Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol (2006) 2.96
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology (2009) 2.92
Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut (2005) 2.90
A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol (2004) 2.84
Causes and metabolic consequences of Fatty liver. Endocr Rev (2008) 2.84
Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology (2008) 2.83
Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology (2008) 2.70
Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology (2001) 2.69
Leptin in immunology. J Immunol (2005) 2.62
Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol (2006) 2.59
Adiponectin--a key adipokine in the metabolic syndrome. Diabetes Obes Metab (2006) 2.58
Nonalcoholic fatty liver disease. CMAJ (2005) 2.56
Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance. J Biol Chem (2007) 2.55
Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. J Hepatol (2004) 2.46
Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology (2003) 2.38
From fat to inflammation. Gastroenterology (2006) 2.35
Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis (2008) 2.35
Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol (2004) 2.28
Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am J Pathol (2003) 2.27
Relation between liver progenitor cell expansion and extracellular matrix deposition in a CDE-induced murine model of chronic liver injury. Hepatology (2009) 2.23
Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology (1998) 2.19
Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol (2002) 2.16
Heterogeneity and plasticity of hepatocyte lineage cells. Hepatology (2001) 2.12
11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med (2005) 2.12
Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol (2001) 2.11
Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol (2004) 2.11
Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology (2002) 2.10
Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology (2006) 2.08
Prevalence of fatty liver in Japanese children and relationship to obesity. An epidemiological ultrasonographic survey. Dig Dis Sci (1995) 2.06
The role of leptin in human obesity and disease: a review of current evidence. Ann Intern Med (1999) 2.05
Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology (2002) 2.04
Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci (1997) 1.99
Serum leptin levels in patients with nonalcoholic steatohepatitis. Am J Gastroenterol (2000) 1.96
Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol (2005) 1.93
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology (2007) 1.92
Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol (2006) 1.90
In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol (2002) 1.86
Angiotensin II activates I kappaB kinase phosphorylation of RelA at Ser 536 to promote myofibroblast survival and liver fibrosis. Gastroenterology (2009) 1.84
Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology (1996) 1.83
Liver fibrosis: cellular mechanisms of progression and resolution. Clin Sci (Lond) (2007) 1.77
Hepatocyte growth factor attenuates liver fibrosis induced by bile duct ligation. Am J Pathol (2006) 1.76
A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther (2006) 1.74
Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab (2005) 1.73
Hepatic injury associated with small bowel bacterial overgrowth in rats is prevented by metronidazole and tetracycline. Gastroenterology (1991) 1.72
Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses. Hepatology (2009) 1.72
Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology (2005) 1.68
Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol (2006) 1.67
Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology (2002) 1.66
Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis. Gastroenterology (2000) 1.63
Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond) (2008) 1.59
Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig Liver Dis (2009) 1.58
A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol (2004) 1.56
Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut (2005) 1.53
Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology (2005) 1.50
Could inflammatory markers help diagnose nonalcoholic steatohepatitis? Eur J Gastroenterol Hepatol (2009) 1.50
Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Semin Liver Dis (2007) 1.49
Relationship between carbohydrate-induced hypertriglyceridemia and fatty acid synthesis in lean and obese subjects. J Lipid Res (2000) 1.42
Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol (2007) 1.41
Effects of interventions in pregnancy on maternal weight and obstetric outcomes: meta-analysis of randomised evidence. BMJ (2012) 5.28
Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2010) 2.28
Elevated cerebrospinal fluid (CSF) leptin in idiopathic intracranial hypertension (IIH): evidence for hypothalamic leptin resistance? Clin Endocrinol (Oxf) (2008) 2.15
11beta-Hydroxysteroid dehydrogenase type 1 regulates insulin and glucagon secretion in pancreatic islets. Diabetologia (2008) 1.07
A novel selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitor prevents human adipogenesis. J Endocrinol (2008) 1.06
11beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. J Clin Endocrinol Metab (2004) 1.05
Birmingham and Lambeth Liver Evaluation Testing Strategies (BALLETS): a prospective cohort study. Health Technol Assess (2013) 1.02
Which hepatocyte will it be? Hepatocyte choice for bioartificial liver support systems. Liver Transpl (2001) 1.01
Expression profiling of 11beta-hydroxysteroid dehydrogenase type-1 and glucocorticoid-target genes in subcutaneous and omental human preadipocytes. J Mol Endocrinol (2006) 1.01
Current therapeutic strategies in non-alcoholic fatty liver disease. Diabetes Obes Metab (2011) 1.00
Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program. Aliment Pharmacol Ther (2012) 0.98
Central hypoadrenalism. J Clin Endocrinol Metab (2014) 0.90
Referral patterns and social deprivation in paracetamol-induced liver injury in Scotland. Lancet (2001) 0.89
Prothrombin time to assess fulminant hepatic failure. Lancet (2002) 0.89
Adrenal suppression in bronchiectasis and the impact of inhaled corticosteroids. Eur Respir J (2008) 0.87
Tissue specific regulation of glucocorticoids in severe obesity and the response to significant weight loss following bariatric surgery (BARICORT). J Clin Endocrinol Metab (2015) 0.86
Growth hormone, insulin-like growth factor-I and the cortisol-cortisone shuttle. Horm Res (2001) 0.85
Effects of the 5-HT2C receptor agonist meta-chlorophenylpiperazine on appetite, food intake and emotional processing in healthy volunteers. Psychopharmacology (Berl) (2014) 0.84
Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis. Diabetes Obes Metab (2014) 0.84
Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis. Gut (2012) 0.82
An improved ex vivo method of primary porcine hepatocyte isolation for use in bioartificial liver systems. Eur J Gastroenterol Hepatol (2000) 0.80
Long-term impact of liver transplantation on respiratory function and nutritional status in children and adults with cystic fibrosis. Am J Transplant (2012) 0.78
Corticosteroids, 11beta-hydroxysteroid dehydrogenase isozymes and the rabbit choroid plexus. J Neuroendocrinol (2007) 0.77
Short- and long-term glucocorticoid treatment enhances insulin signalling in human subcutaneous adipose tissue. Nutr Diabetes (2011) 0.76
Editorial: Treatment for NASH - helping the liver or helping the heart? Aliment Pharmacol Ther (2015) 0.75
Platelet basal cytosolic calcium: the influence of plasma factors in cirrhosis. J Hepatol (1996) 0.75